RE:RE:RE:RE:RE:RE:Anakinra Attenuates Glioblastoma AggressivenessTrue, poof, Midatech is pumping xB3. That makes sense. They're promoting their acquisition. The Bioasis corporate presentation went from 55 pages, mostly about xB3, and dropped down to 17 pages, with only 2 pages about xB3.
Why?
Don't they love xB3 no more?
Simple question.
poof, the answer isn't that Midatech is promoting xB3. The real question is why Bioasis gave up publicly promoting the huge potential value of xB3?
The answer lies in the difficulty DrDR has promoting this terrible deal. How can DrDR make the case for selling Bioasis for 4¢ if xB3 has such huge potential value? Tens if billions of potential revenue per year!!!!!
I maintain that she knew she couldn't justify the sellout with xB3 being considered to be so valuable. I maintain that she started downplaying the value of xB3 last year because she understood that situation.
About Scarpa's Hunter preclinical work and xB3-001, Bioasis did sufficient work with xB3-001 to justify a pre-IND submission to the FDA. DrDR promoted the FDA's favourable response.
But there are more questions, poof. I'll let you get on with them.
JD